Calithera Biosciences (CALA) to Release Earnings on Tuesday

Calithera Biosciences (NASDAQ:CALA – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 10th. Analysts expect Calithera Biosciences to post earnings of ($0.17) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Calithera Biosciences (NASDAQ:CALA – Get Rating) last issued its earnings results on Thursday, March 31st. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. On average, analysts expect Calithera Biosciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Calithera Biosciences stock opened at $0.24 on Monday. Calithera Biosciences has a 52-week low of $0.23 and a 52-week high of $2.59. The company has a 50-day simple moving average of $0.40 and a two-hundred day simple moving average of $0.66.

Several research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Calithera Biosciences in a report on Wednesday, May 4th. They issued a “hold” rating for the company. SVB Leerink decreased their target price on shares of Calithera Biosciences from $3.00 to $2.00 and set an “outperform” rating for the company in a report on Monday, April 4th. LADENBURG THALM/SH SH began coverage on shares of Calithera Biosciences in a report on Monday, January 31st. They issued a “buy” rating and a $4.00 target price for the company. Finally, Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Calithera Biosciences currently has an average rating of “Hold” and an average target price of $2.63.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CALA. Virtu Financial LLC grew its position in Calithera Biosciences by 1,205.4% during the fourth quarter. Virtu Financial LLC now owns 232,198 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 214,410 shares during the period. Bank of America Corp DE grew its position in Calithera Biosciences by 90.4% during the second quarter. Bank of America Corp DE now owns 100,212 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 47,568 shares during the period. JPMorgan Chase & Co. grew its position in Calithera Biosciences by 44.4% during the fourth quarter. JPMorgan Chase & Co. now owns 547,914 shares of the biotechnology company’s stock valued at $364,000 after buying an additional 168,388 shares during the period. Renaissance Technologies LLC grew its position in Calithera Biosciences by 258.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,357,400 shares of the biotechnology company’s stock valued at $903,000 after buying an additional 978,800 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its position in Calithera Biosciences by 2,823.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,518,553 shares of the biotechnology company’s stock valued at $1,010,000 after buying an additional 1,466,611 shares during the period. 55.84% of the stock is owned by hedge funds and other institutional investors.

Calithera Biosciences Company Profile (Get Rating)

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.

Featured Stories